Merrem I.V. Shortage Due To Increased Regional Demand, AstraZeneca Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s website states the antibiotic shortage stems from “manufacturing delays due to bulk drug supply shortages.” The company does not plan to ration shipments to U.S. regions that are not experiencing increased demand.
You may also be interested in...
Merrem I.V. Shortage May Continue Into 2006
Short supply of AstraZeneca's antibiotic is attributed to manufacturing delays and increased demand.
Merrem I.V. Shortage May Continue Into 2006
Short supply of AstraZeneca's antibiotic is attributed to manufacturing delays and increased demand.
Pediatric Studies For AstraZeneca’s Merrem Referred To NIH
The National Institutes of Health is seeking input on a study request for meropenem in children less than three moths old with complicated intra-abdominal infections. The request includes a randomized, active controlled study and a pharmacokinetic study.